Investigating how specific tumor markers affect lung cancer treatment responses
HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy
This study is looking at how certain genetic markers in lung cancer tumors might affect how well a specific immunotherapy works, and it's for patients with non-small cell lung cancer who have a certain genetic type, helping to find more personalized treatment options for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10994035 on NIH RePORTER |
What this research studies
This research focuses on non-small cell lung cancer (NSCLC) and aims to understand how certain genetic markers, known as motif neoepitopes, influence the effectiveness of PD-1 inhibitors, a type of immunotherapy. By analyzing tumor samples from patients with specific HLA-B44 alleles, the study will explore the tumor microenvironment and how it varies between patients with and without these markers. The approach includes examining gene expression and cellular composition to identify potential predictors of treatment success. This could lead to more personalized treatment strategies for lung cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who possess HLA-B44 supertype alleles.
Not a fit: Patients without non-small cell lung cancer or those who do not have HLA-B44 supertype alleles may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could help identify which lung cancer patients are more likely to benefit from PD-1 inhibitors, leading to improved treatment outcomes.
How similar studies have performed: Previous research has shown promising results in using genetic markers to predict responses to immunotherapy, suggesting that this approach may yield valuable insights.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Garon, Edward B — University of California Los Angeles
- Study coordinator: Garon, Edward B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.